Prosecution Insights
Last updated: April 19, 2026

Examiner: HA, JULIE

Tech Center 1600 • Art Units: 1654 1675

This examiner grants 76% of resolved cases

Performance Statistics

75.6%
Allow Rate
+15.6% vs TC avg
1143
Total Applications
+44.3%
Interview Lift
982
Avg Prosecution Days
Based on 1099 resolved cases, 2023–2026

Rejection Statute Breakdown

4.4%
§101 Eligibility
15.1%
§102 Novelty
27.4%
§103 Obviousness
18.5%
§112 Clarity

Currently Pending Office Actions

App #TitleStatusAssignee
19369023 ANTI-ISCHEMIC COMPOSITIONS Non-Final OA FAGRELL, BENGT
18017041 CO-AGONISTS AT GLP-1 AND GIP RECEPTORS SUITABLE FOR ORAL DELIVERY Non-Final OA Novo Nordisk A/S
17598010 GLUCOSE SENSITIVE INSULIN DERIVATIVES Non-Final OA Novo Nordisk A/S
18012288 METHOD AND COMPOSITION FOR REDUCING OR PREVENTING BONE RESORPTION Non-Final OA University of Connecticut
17908825 ANTIVIRAL STRUCTURALLY-STABILIZED SARS-CoV-2 PEPTIDES AND USES THEREOF Non-Final OA Dana-Farber Cancer Institute, Inc.
17916170 CASPASE INHIBITORS TO ENHANCE INJURY REPAIR AND TO TREAT BACTERIAL AND VIRAL INFECTIONS Non-Final OA The Johns Hopkins University
18174158 METHODS, SYSTEMS, AND COMPOSITIONS FOR LEGUME-BASED PRODUCTION OF THERAPEUTIC PROTEINS AND THERAPEUTIC MEDICAL MATERIALS Non-Final OA Arizona Board of Regents on Behalf of The University of Arizona
18652429 TUMOR ASSOCIATED MONOCYTE/MACROPHAGE BINDING PEPTIDE AND METHODS OF USE THEREOF Non-Final OA Sanford Burnham Prebys Medical Discovery Institute
17759634 ALLERGEN PROTECTION FOR THE SKIN Non-Final OA BEIERSDORF AG
17759635 TOPICALLY APPLICABLE PREPARATION COMPRISING PEPTIDES AS ALLERGEN PROTECTION FOR THE SKIN Final Rejection BEIERSDORF AG
17908015 Undenatured Type II Collagen in Food and Beverage Applications and Uses Thereof Final Rejection Lonza Greenwood LLC
18510327 GROWTH HORMONE ANTAGONIST AND ANTI-CANCER COMPOSITION COMBINATION THERAPY Non-Final OA Molecular Technologies Laboratories LLC
17908532 COMPOUNDS FOR USE IN AUTOIMMUNE CONDITIONS Non-Final OA PHARMA MAR, S.A.
17920598 LACTIC ACID BACTERIA GROWTH PROMOTER Non-Final OA Asahi Group Holdings, Ltd.
17299795 VASODILATORS FOR USE IN THE TREATMENT OF A RETINAL ISCHEMIC DISORDER Non-Final OA Rigshospitalet
18037463 TETRAPEPTIDE AND COMPOSITIONS COMPRISING TETRAPEPTIDES Non-Final OA THE BOOTS COMPANY PLC
17905907 EFFICIENT PREPARATION OF DOLASTATIN AND AURISTATIN ANALOGS THROUGH A COMMON INTERMEDIATE Non-Final OA Sigma-Aldrich Co. LLC
17922487 METHODS OF TREATMENT COMPRISING STABLE REDUCED GLUTATHIONE Non-Final OA Professional Nutraceutical Design, LLC
17917858 COMPOSITIONS AND USES OF LOCALLY APPLIED SYNTHETIC AMINO ACID POLYMERS FOR PREVENTION AND TREATMENT OF VIRAL INFECTIONS Non-Final OA Amicrobe, Inc.
17912247 COMPOSITIONS HAVING MULTIPLE RECOMBINANT HUMAN GROWTH FACTORS INCLUDED THEREIN FOR REDUCING SIGNS OF AGING Non-Final OA SkinGen international Inc.
17906003 USE OF ANTI-AGING GLYCOPEPTIDES FOR TREATMENT OF DRY EYE DISEASE, RETINAL DEGENERATIVE DISEASES, OR OCCULAR INFLAMMATION Non-Final OA Protokinetix Inc.
17795836 OPHTHALMIC PHARMACEUTICAL COMPOSITION AND USE THEREOF Non-Final OA FERRER INTERNACIONAL, S.A.
17793545 NEUTROPHIL ELASTASE BINDING PEPTIDES AND COMPOSITIONS THEREOF Non-Final OA The United States Govemment as Represented by the Department of Veteran Affairs
17439590 STABILIZATION OF PRANDIAL OR BASAL INSULIN ANALOGUES BY AN INTERNAL DISELENIDE BRIDGE Non-Final OA YISSUM RESEARCH AND DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD.

Facing This Examiner?

IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.

Build Your Strategy

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month